JAAD Case Reports · 2019 · 41 citations · 4 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmune CheckpointsImmune-related Adverse EventsCtla-4 InhibitionCytotoxic T-lymphocyte-associated Protein 4 InhibitorsDress SyndromeImmune Checkpoint DysregulationImmune Checkpoint LigandsImmune Checkpoint ReceptorsImmune Checkpoint ResistanceImmune-mediated Adverse Events
The recent development of immune checkpoint inhibitors such as PD-1/PD-L1 inhibitors and CTLA-4 inhibitors has revolutionized the approach to cancer therapy. However, with these advances comes a distinctive set of toxic effects, collectively named immune-related adverse events (IRAEs).
4